Last reviewed · How we verify
ASP6294
ASP6294 is a small molecule inhibitor of the PI3K delta subunit.
ASP6294 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | ASP6294 |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, ASP6294 is expected to modulate immune cell function and potentially treat various immune-related disorders.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
Key clinical trials
- A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis (PHASE2)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP6294 CI brief — competitive landscape report
- ASP6294 updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI